注册 登录  
 加关注
   显示下一条  |  关闭
温馨提示!由于新浪微博认证机制调整,您的新浪微博帐号绑定已过期,请重新绑定!立即重新绑定新浪微博》  |  关闭

zliming2004的博客

新药研发与药物合成

 
 
 

日志

 
 
 
 

A close look at LCZ696: Novartis success comes from BMS failure  

2015-02-03 13:11:17|  分类: 药物化学 |  标签: |举报 |字号 订阅

  下载LOFTER 我的照片书  |

Novartis released results of new heart failure drug LCZ696 from PARADIGM-HF trial on the weekend[1]. LCZ696 was tested against enalapril, the standard therapy, in patients with heart failure. This new drug reduced cardiovascular death by 20% and heart failure hospitalization by 21%.

These data suggest that LCZ696 could replace angiotensin-converting enzyme (ACE) inhibitors that have been central to treating heart failure for more than 20 years. David Epstein, the head of Novartis Pharmaceuticals, described LCZ696 as the most exciting new drug ever. Analysts such as Seamus Fernandez, Damien Conover and Timothy Anderson hiked their forecast to $6-8 billion a year in peak sales.

LCZ696 is a combination of valsartan and sacubitril (AHU377) in a 1:1 mixture. Valsartan is an angiotensin II receptor antagonist while sacubitril is a prodrug of LBQ657 which inhibits neprilysin (NEP).

This isn’t the first time that a drug inhibits renin-angiotensin system and NEP at the same time. Bristol-Myers Squibb had a drug called omapatrilat which inhibits both NEP and ACE. Unfortunately, its development was discontinued due to the increased risk of angioedema, a deadly side effect that can cause patients to suffocate.

What interests me most is that Novartis succeeded in which Bristol-Myers Squibb had failed.

Angioedema is thought to be mediated by bradykinin which is degraded by ACE, APP, NEP and DPP-4[2]. Omapatrilat not only inhibits ACE, but also inhibits NEP and APP. Inhibition of all three enzymes may greatly increase bradykinin, resulting in angioedema.

Angioedema caused by angiotensin II receptor antagonists is much less than that for ACE inhibitors. Novartis’s new combination inhibits only NEP and APP, thereby producing beneficial cardiovascular effects without the side effect of angioedema.

There is no rose without thorn. As William Foster mentions, the natriuretic peptides are not the only substrates of NEP. NEP also degrades the amyloid beta peptide which is strongly linked to Alzheimer’s disease (AD). Inhibition of NEP might lead to an increased level of beta-amyloid and thus an increased risk of AD. Further monitoring for neurological dysfunction is warranted.

[1] N Engl J Med. 2014, doi: 10.1056/NEJMoa1409077.

[2] Br J Pharmacol. 2008, 153(5), 947-955.

  评论这张
 
阅读(23)| 评论(0)
推荐 转载

历史上的今天

评论

<#--最新日志,群博日志--> <#--推荐日志--> <#--引用记录--> <#--博主推荐--> <#--随机阅读--> <#--首页推荐--> <#--历史上的今天--> <#--被推荐日志--> <#--上一篇,下一篇--> <#-- 热度 --> <#-- 网易新闻广告 --> <#--右边模块结构--> <#--评论模块结构--> <#--引用模块结构--> <#--博主发起的投票-->
 
 
 
 
 
 
 
 
 
 
 
 
 
 

页脚

网易公司版权所有 ©1997-2017